ImageneBio

Executive Summary

ImageneBio is a clinical-stage biotechnology company pioneering next-generation therapies for autoimmune and inflammatory diseases. Its lead asset, IMG-007, is an investigational anti-OX40 monoclonal antibody engineered with enhanced pharmacokinetics and reduced immunogenicity compared to first-generation OX40 antagonists. OX40 is a key costimulatory receptor on activated T cells, and its blockade has shown promise in atopic dermatitis, asthma, and other Th2-mediated conditions. Preclinical studies suggest IMG-007 may offer improved durability and safety, positioning it as a potential best-in-class therapy. Currently in Phase 1 trials, ImageneBio aims to demonstrate safety, tolerability, and early efficacy signals. The company is privately held and operates out of San Diego, leveraging a lean team to advance its pipeline. With a large addressable market and a differentiated mechanism, ImageneBio represents a compelling opportunity in the autoimmune space, though it remains early-stage with typical clinical risks.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Safety and PK/PD Data Readout60% success
• Q1 2027Initiation of Phase 2 Trial in Atopic Dermatitis50% success
• TBDPotential Strategic Partnership or Licensing Deal40% success